Skip to main content
. 2017 Dec;45:249–257. doi: 10.1016/j.tiv.2017.03.004

Fig. 7.

Fig. 7

A. Concentration – time profile curves from the PBK model built for caffeine and relevant metabolites (corresponding to the PBK model workflow in Fig. 4A). B. PBK model simulation of viability – dose response for oral and dermal exposure (corresponding to the PBK model workflow in Fig. 4B).